Pharmaceuticals

Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams

New IBD research shows that, even during clinical remission, people living with Crohn's diseasecontinue to experience greater work impairment than the general population The new campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endo...

2025-09-30 10:00 2046

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

* HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("...

2025-09-29 20:48 1268

Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital

LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition...

2025-09-29 12:58 1771

Tourism Malaysia and MHTC Bring Malaysia Fair 2025 to Surabaya A Celebration of Culture, Cuisine, Travel, and Healthcare Excellence

SURABAYA, Indonesia, Sept. 26, 2025 /PRNewswire/ -- Tourism Malaysia, in collaboration with the Malaysia Healthcare Travel Council (MHTC), proudly presents Malaysia Fair 2025—a four-day celebration ofMalaysia's culture, cuisine, tourism, and healthcare excellence. Taking place at Pakuwon Mall, Su...

2025-09-26 09:45 2947

ADVANCION PUBLISHES 2024 CORPORATE SUSTAINABILITY REPORT

Fourth annual report highlights continued progress in sustainable innovation, safety, and responsible resource stewardship BUFFALO GROVE, Ill., Sept. 25, 2025 /PRNewswire/ -- Advancion Corporation ("Advancion" or "Company"), a global leader in life science buffers and proprietary specialty ingre...

2025-09-25 02:40 1651

The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)

* Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2 * Elevated lipoprotein(a) or Lp(a), an inherited condition that raises CVD risk, affects 1 in 5 people worldwide but is rarely tested3 * New survey across Asia Pacific and Middle East s...

2025-09-24 20:21 1850

Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Glenmark Specialty S.A. (GSSA), a whol...

2025-09-24 19:45 2024

Xinhua Silk Road: Guotai Haitong Securities hosts conference on biopharma and AI in E. China's Shanghai

BEIJING, Sept. 24, 2025 /PRNewswire/ -- The 2025 Shanghai pioneering industries conference, hosted by Guotai Haitong Securities, was recently held in east China's Shanghai. The event also featured the 14th pharmaceutical CEO forum and the 5th artificial intelligence (AI) conference. The event bro...

2025-09-24 09:02 2628

TraceLink Delivers Intelligent Productivity Gains with OPUS Platform Expansion

BOSTON, Sept. 24, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced powerful new capabilities in its Orchestration Platform for Universal Solutions (OPUS) designed to unlock unprecedented productivity...

2025-09-24 00:12 1423

LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services

JOHNSON CITY, Tenn., Sept. 23, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, announces a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities. As demand for radiopharmac...

2025-09-23 21:15 1309

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics

2025-09-23 20:01 1439

Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress

CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- The 2025 European Society for Medical Oncology (ESMO) Congress will take place inBerlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) will present results from multiple clinical stud...

2025-09-23 17:03 1866

Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC

CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review ...

2025-09-23 10:22 1569

IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training

MELBOURNE, Australia, Sept. 23, 2025 /PRNewswire/ -- IMRA Surgical, an Australian-based company at the forefront of disruptive technology for surgical training solutions announces a collaboration with Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") a global leader in radiopharmaceu...

2025-09-23 05:19 1785

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer

BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS  (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its ...

2025-09-22 20:00 1702

Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First Dedicated Cancer Centre for Women

NEW DELHI, Sept. 22, 2025 /PRNewswire/ -- Apollo Hospitals Enterprise Ltd (AHEL) recently announced the launch ofApollo Athenaa – Asia's First Dedicated Cancer Centre for Women, located in E2-E3, Defence Colony, New Delhi. The centre was inaugurated by the Hon'ble Chief Minister ofDelhi, Smt. Rek...

2025-09-22 15:43 2509

First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs

NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 onSeptember 19, ...

2025-09-22 12:29 2195

Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic m...

2025-09-19 20:00 2765

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg...

2025-09-19 19:59 3812

LabConnect Appoints Bill Finger as Senior Vice President, Global Strategic Services

JOHNSON CITY, Tenn., Sept. 19, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Bill Finger as Senior Vice President, Global Strategic Services, effectiveWednesday, September 10, 2025.  Bill brings more than 25 years of diagnostics and clinical research experience, with ...

2025-09-19 01:25 1990
1 ... 11121314151617 ... 186